Loading...
Market
Will insulin prices in the US decrease by at least 10% as a result of the FTC lawsuit by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official pharmaceutical pricing data and reports
Story
FTC Sues CVS, Cigna, UnitedHealth Over Inflated Insulin Prices and Rebate Programs
Sep 20, 2024, 04:49 PM
The Federal Trade Commission (FTC) has filed a lawsuit against the three largest pharmacy benefit managers (PBMs) in the United States—CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx. The FTC accuses these PBMs of artificially inflating the prices of insulin through illegal rebate programs and steering diabetic patients towards higher-priced insulin products to reap millions of dollars in rebates from pharmaceutical companies. The lawsuit alleges that these practices have significantly increased the cost of insulin, with prices spiking by over 1,200 percent over the past two decades. These three PBMs administer 80% of medication in the US. The FTC has also put drugmakers on notice. The FTC's action aims to address these anticompetitive practices and restore competition in the insulin market.
View original story
Similar markets
Yes • 50%
No • 50%
Insulin prices decrease significantly • 25%
Insulin prices decrease slightly • 25%
Insulin prices remain the same • 25%
Insulin prices increase • 25%
Decrease by more than 20% • 25%
Decrease by 10-20% • 25%
Decrease by less than 10% • 25%
No significant change • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Eli Lilly • 33%
Novo Nordisk • 33%
Sanofi • 33%
None • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%